Allogene Therapeutics, Inc.
ALLODrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ALLO Earnings Report
EPS Est: $-0.16 | FQ end 2026-06 | Call: 2026-08-12 16:00:00
How ALLO's past catalysts played out
Fludarabine
Large B-cell Lymphoma
ALLO-647
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fludarabine | Phase 2 | Large B-cell Lymphoma | - | - |
ALLO-647 | Phase 2 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Allogene Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Allogene Therapeutics, Inc.'s (ALLO) pipeline across Phase 2. Its lead program is Fludarabine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Allogene Therapeutics, Inc.'s next FDA catalyst?→
Allogene Therapeutics, Inc.'s (ALLO) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALLO biotech catalysts?→
Add ALLO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Allogene Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.